Date: 2015-06-02
Type of information: Licensing agreement
Compound: human antibodies against CD19
Company: Genmab (Denmark) BMS (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: monoclonal antibody
Disease: hematologic cancers
Details: * On June 2, 2015, Genmab announced it has entered into an agreement for an exclusive license from BMS to a panel of human antibodies targeting CD19 together with associated intellectual property. The CD19 protein expressed on certain hematologic cancer cells is seen as a promising target for the treatment of these cancers. The deal is part of Genmab\'s strategy to create a broad pipeline of innovative therapeutic products, using the company\'s in house know-how and antibody expertise to create truly differentiated cancer therapeutics. \"CD19 is a clinically-validated target for therapy of certain blood cancers and this exclusive license allows us to create truly differentiated next-generation antibody drugs using our deep understanding of antibody biology, which could lead to new ways of treating cancer. Genmab\'s strength lies in our world-class antibody capabilities and our ability to turn science into medicine, which allows us to help patients whilst building a sustainably profitable business,\" said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Financial terms: Genmab will make a one-time $ 4 million licensing payment to Bristol-Myers Squibb upon execution of the license. Other financial terms of the agreement were not disclosed.
Latest news:
